Triple therapy using direct-acting agents for recurrent hepatitis C after liver transplantation: A single-center experience

T. Ikegami, T. Yoshizumi, Y. Soejima, N. Harimoto, S. Itoh, K. Takeishi, H. Uchiyama, H. Kawanaka, Y. I. Yamashita, E. Tsujita, N. Harada, E. Oki, H. Saeki, Y. Kimura, K. Shirabe, Y. Maehara

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Background Hepatitis C viral graft reinfection is almost a universal event after liver transplantation with consequent disease progression. Methods We applied triple therapy (n = 21) with the use of telaprevir (TVR; n = 12) or simeprevir (SVR; n = 9). Results TVR was given at the dose 1,500 mg daily (n = 11) with reduced dose of cyclosporine at 25% to 50%, and SVR was given at the dose 100 mg daily with unadjusted cyclosporine, followed by 12 weeks of dual therapy. The early viral response was achieved in 91.7% (n = 11), end of treatment response rate was 91.7% (n = 11), and sustained viral response rate was 83.3% (n = 10) in the TVR group, and respective rates were 88.9% (n = 8), 77.8% (n = 7), and 77.8% (n = 7) in the SVR group. Although granulocyte colony-stimulating factor was not given in the patients with triple therapy, blood transfusion was performed in 7 cases (58.3%) in the TVR group and 1 case (11.1%) in the SVR group. Interferon-mediated graft dysfunction was observed in 4 cases (33.3%) in the TVR group and 3 cases (33.3%) in the SVR group, respectively. The cumulative viral clearance rates in triple (n = 21) and dual (n = 105) therapy were 95.0% and 18.1% at 12 weeks, and 95.0% and 40.0%, respectively, at 24 weeks (P <.01). Conclusions Although careful monitoring for possible adverse events is required during treatment, triple therapy with the use of direct-acting agents are very effective in treating hepatitis C after liver transplantation.

Original languageEnglish
Pages (from-to)730-732
Number of pages3
JournalTransplantation Proceedings
Volume47
Issue number3
DOIs
Publication statusPublished - Apr 1 2015

All Science Journal Classification (ASJC) codes

  • Surgery
  • Transplantation

Fingerprint Dive into the research topics of 'Triple therapy using direct-acting agents for recurrent hepatitis C after liver transplantation: A single-center experience'. Together they form a unique fingerprint.

Cite this